Author's response to reviews

Title: Target molecule therapy for Kaposis sarcoma in a Kidney Transplant Patient: case report, what worked, what not.

Authors:

Patricia Volkow (volkow@perezpadilla-volkow.com.mx)
Ricardo Correa-Rotter (correarotter@prodigy.net.mx)
Juan W Zinser (juanwzinser@infosel.net.mx)

Version: 2 Date: 10 August 2006

Author's response to reviews: see over
To the editor  
BioMed Nephrology

Enclose please find the manuscript: **Target molecule therapy for Kaposi’s sarcoma in a Kidney Transplant Patient: case report,” what worked, what not”**.

To be consider for publication in Nephrology. We consider it of importance and interest to the readers, as Kaposi’s sarcoma therapy is even nowadays not established, and different therapeutics approaches had been used. Recently it was published an experience with the use of imatinib for AIDS-related Kaposi’s sarcoma, where the authors considered it was of clinical benefit. As it happened with the case here reported, physicians could attain the compassionate use of this drug in patients with refractory Kaposi’s sarcoma. Whereas the experience with sirlomus, in two other publications, has shown sustain regression, with the dual benefit, prevent graft rejection and KS regression. We think the case is relevant, because the patient showed sustained regression after a long-standing and multiple chemotherapy regimes.

It has not been published in other journal nor considered for publication elsewhere. We have written consent from the patient to publish this case.

No conflicts of interest can be reported for any of the authors.

Dr. Patricia Volkow
Address correspondence to:
   Patricia Volkow
   Departamento de Enfermedades Infecciosas
   Instituto Nacional de Cancerología
   Av. San Fernando 22
   México D.F. CP 14080.
   Email volkow@perezpadilla-volkow.com.mx
Telephone 55 52 56280447
Fax 55 52 55139743